Chinook Therapeutics Inc represents values and a corporate philosophy focused on advancing precision medicine to develop transformative therapies for patients with kidney diseases and other rare disorders. By leveraging innovative science and strategic partnerships, Chinook aims to bring novel treatments to those in need. The company's core principles include a patient-centric approach, scientific rigor, collaboration, and commitment to improving patient outcomes. Through their dedication to addressing unmet medical needs, Chinook Therapeutics Inc strives to make a meaningful impact in the lives of patients worldwide.

Chinook Therapeutics Inc is primarily present in the United States and Canada.

Chinook Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in January 2020, raising substantial funds to support its research and development efforts. They have also entered into strategic partnerships and collaborations with industry leaders, enhancing their potential for breakthrough innovations. Notably, Chinook Therapeutics has made progress in advancing their pipeline of novel precision medicines focused on tackling kidney diseases, including the development of their lead candidate, BION-1301. These achievements demonstrate Chinook Therapeutics Inc's commitment to transforming the treatment landscape and improving the lives of patients affected by kidney-related conditions.

Chinook Therapeutics Inc. is a cutting-edge biotechnology company focused on developing innovative therapies for kidney diseases. Founded in 2019, the company combines world-class expertise in kidney biology with proprietary insights into kidney targets. Chinook Therapeutics aims to tackle the significant unmet medical needs of patients with kidney diseases by advancing its portfolio of precision medicines. By leveraging strategic collaborations and a deep understanding of kidney biology, the company is dedicated to improving the lives of patients suffering from these debilitating conditions. With its talented team and transformative therapies, Chinook Therapeutics continues to make strides in the field of kidney disease treatment.

Some of the main competitors of Chinook Therapeutics Inc in the market include companies like Vertex Pharmaceuticals Inc, Reata Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Chinook Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the healthcare sector, Chinook is focused on developing precision medicines for patients with kidney diseases and other severe conditions. With its innovative approach and dedicated research efforts, Chinook Therapeutics Inc aims to address unmet medical needs and improve the lives of individuals affected by these illnesses. Through its groundbreaking therapies and advancements in the biotech field, Chinook is making significant contributions to the healthcare industry.

Chinook Therapeutics Inc is a biotechnology company focused on discovering and developing precision medicines for kidney diseases. Their business model revolves around utilizing advanced technologies and targeting specific pathways to identify and develop potential therapeutic solutions for patients with rare and common kidney disorders. By combining their expertise in kidney biology and precision medicine, Chinook Therapeutics aims to address the significant unmet medical needs in the field of kidney disease treatment. With a dedicated focus on innovative drug development and strategic partnerships, Chinook Therapeutics Inc strives to improve the lives of patients through their cutting-edge therapies.

Chinook Therapeutics KGV ir -10,29.

Chinook Therapeutics KUV ir 195,82.

AlleAktien kvalitātes vērtējums Chinook Therapeutics ir 5/10.

gaidāmā Chinook Therapeutics apgrozījums ir 13,28 milj. USD.

gaidāmā Chinook Therapeutics peļņa ir -252,77 milj. USD.

Chinook Therapeutics Inc is a biotechnology company specializing in the discovery and development of drugs for the treatment of rare and deadly kidney diseases. The company was founded in 2018 and is headquartered in Seattle, Washington. Chinook has built a comprehensive platform for the discovery and development of drugs based on genetic insights into kidney diseases and their progression. The company invests in targeted identification and validation of targets to identify new and innovative therapeutics that have the potential to change the treatment of kidney diseases. The business model of Chinook Therapeutics includes three main areas: research and development, clinical development, and partnerships. In the research and development area, Chinook invests in the identification and validation of new targets for the prevention and treatment of kidney diseases. Clinical development involves conducting clinical trials for new drugs to test their safety and efficacy in treating various medical conditions. Chinook currently has several promising drug candidates in various stages of clinical development, including appropriate patient populations for a genetically defined kidney disease. Chinook's partnerships with leading companies in the pharmaceutical and biotechnology industry have positive implications for the development and market launch of new medical products. Chinook collaborates with leading pharmaceutical companies for clinical trials and joint research projects to develop innovative drugs for patients. The company's broad portfolio includes a range of innovative therapeutics that have the potential to significantly improve the treatment of kidney diseases. The products include: BION-1301, an antibody targeting a pathway responsible for the progression of IgA nephropathy; CHK-336, a drug targeting the ApoL1 protein associated with kidney diseases and the progression of kidney diseases; and Speedy Study, a clinical trial investigating the use of Low-Dose Interleukin-2 (LDIL-2) for the treatment of lupus nephritis. Overall, Chinook Therapeutics has built a scientifically grounded business model that provides a strong foundation for the development and commercialization of novel therapeutics against kidney diseases. The investment in targeted identification and validation of targets, collaboration with leading researchers and key opinion leaders, and close cooperation with strategic partners in clinical trials will help Chinook successfully bring its innovative products to the market.

Chinook Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Chinook Therapeutics vai uzņēmums nedod dividendes.

Chinook Therapeutics ISIN ir US16961L1061.

Chinook Therapeutics WKN ir A2QE43.

Chinook Therapeutics simbols ir KDNY.

Pēdējo 12 mēnešu laikā Chinook Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Chinook Therapeutics plāno maksāt dividendes 0 USD apmērā.

Chinook Therapeutics pašreizējā dividendu rentabilitāte ir .

Chinook Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Chinook Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Chinook Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Chinook Therapeutics apmērā 0 USD, kas tika izmaksāta 20.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.11.2024..

Pēdējās dividendes izmaksa notika 20.11.2024..

Gadā 2023, Chinook Therapeutics izmaksāja 0 USD dividendes.

Chinook Therapeutics dividendes tiek izmaksātas USD.